Allogene Therapeutics (ALLO) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 2.3% versus a loss of 4.8%. Over five years, DRUG leads with a +40.0% price change compared with -91.5% for ALLO. Bright Minds Biosciences is the larger company by market cap ($512.9 million vs $483.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | DRUG |
|---|---|---|
| Share price | $1.40 | $52.00 |
| Market cap | $483.69M | $512.93M |
| 1-day change | -2.10% | 0.00% |
| YTD return | +2.19% | -33.37% |
| 1-year return | -4.76% | +2.30% |
| 5-year return | -91.50% | +39.97% |
| EPS (TTM) | $-0.66 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $123.75 |
| 52-week low | $1.04 | $47.23 |
| Distance from 52-week high | -68.61% | -57.98% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +542.86% | +192.25% |
| Average volume | 5.65M | 159.01K |
| Shares outstanding | 345.49M | 9.86M |
| Employees | 150 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
ALLO vs DRUG FAQ
Which is bigger, Allogene Therapeutics or Bright Minds Biosciences?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $512.93M compared with $483.69M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or DRUG?
DRUG returned +2.30% over the past 12 months, compared with -4.76% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Bright Minds Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Allogene Therapeutics and Biotechnology: Pharmaceutical Preparations for Bright Minds Biosciences.